VANCOUVER, B.C. – Feb. 22, 2018 (GLOBE NEWSWIRE) – NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX-V:NU) (OTCQB:NRXCF) (Frankfurt:1N9) is pleased to announce it has been named to the 2018 TSX Venture 50®, an annual ranking of top-performing companies on the TSX Venture Exchange over the last year, ranking 10th overall.
Each year, the TSX Venture 50® ranking showcases listed companies that have shown notable results in key measures of market performance. The companies included in the 2018 TSX Venture 50® were selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume.
Glen Rehman, CEO of NeutriSci, stated: “We are pleased to report that NeutriSci has placed as one of the top life sciences companies selected for the 2018 TSX Venture 50. This recognition serves to validate the Company’s strategic execution in 2017. We anticipate extending that same strategy into 2018 by expanding distribution both domestically and globally.”
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
CEO & President
Tel: (403) 264-6320
NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. NeutriSci is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries. For more information, please visit: www.neutrisci.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease.